TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
Clinical trial NCT07330037 · RECRUITING
Trial details
- NCT number
- NCT07330037
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-01
- Primary completion
- 2026-12-31
- Enrollment
- 41
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.